These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 38457226

  • 21. Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma.
    Abou-Alfa GK, Bibeau K, Schultz N, Yaqubie A, Millang B, Ren H, Féliz L.
    Target Oncol; 2022 Sep; 17(5):517-527. PubMed ID: 36114955
    [Abstract] [Full Text] [Related]

  • 22. Hemoglobin and Neutrophil Count as Prognostic Factors in Cholangiocarcinoma Patients in 2nd Line Treatment Setting: Results from a Small Monocentric Retrospective Study.
    Liguori C, Copparoni C, Felicetti C, Pecci F, Lupi A, Pinterpe G, Berardi R, Giampieri R.
    Curr Oncol; 2023 Jan 11; 30(1):1032-1045. PubMed ID: 36661728
    [Abstract] [Full Text] [Related]

  • 23. Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma.
    Kobayashi S, Terashima T, Shiba S, Yoshida Y, Yamada I, Iwadou S, Horiguchi S, Takahashi H, Suzuki E, Moriguchi M, Tsuji K, Otsuka T, Asagi A, Kojima Y, Takada R, Morizane C, Mizuno N, Ikeda M, Ueno M, Furuse J.
    Cancer Sci; 2018 Aug 11; 109(8):2549-2557. PubMed ID: 29856900
    [Abstract] [Full Text] [Related]

  • 24. FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma.
    Guion-Dusserre JF, Lorgis V, Vincent J, Bengrine L, Ghiringhelli F.
    World J Gastroenterol; 2015 Feb 21; 21(7):2096-101. PubMed ID: 25717243
    [Abstract] [Full Text] [Related]

  • 25. High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin.
    Huh G, Ryu JK, Chun JW, Kim JS, Park N, Cho IR, Paik WH, Lee SH, Kim YT.
    BMC Cancer; 2020 Sep 23; 20(1):907. PubMed ID: 32967632
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.
    Furuse J, Okusaka T, Ohkawa S, Nagase M, Funakoshi A, Boku N, Yamao K, Yamaguchi T, Sato T.
    Cancer Chemother Pharmacol; 2009 Dec 23; 65(1):113-20. PubMed ID: 19404641
    [Abstract] [Full Text] [Related]

  • 28. The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Based on FOLFIRI for Advanced Intrahepatic Cholangiocarcinoma as Second-Line and Successive Treatment: A Real-World Study.
    Huang P, Huang X, Zhou Y, Yang G, Sun Q, Shi G, Chen Y.
    Can J Gastroenterol Hepatol; 2022 Dec 23; 2022():9680933. PubMed ID: 36199981
    [Abstract] [Full Text] [Related]

  • 29. Retrospective analysis of survival benefits of chemotherapy for metastatic or non-resectable intrahepatic cholangiocarcinoma.
    Wiazzane N, Chauffert B, Ghiringhelli F.
    Clin Res Hepatol Gastroenterol; 2013 Dec 23; 37(6):614-8. PubMed ID: 23711827
    [Abstract] [Full Text] [Related]

  • 30. A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma.
    Sohal DP, Mykulowycz K, Uehara T, Teitelbaum UR, Damjanov N, Giantonio BJ, Carberry M, Wissel P, Jacobs-Small M, O'Dwyer PJ, Sepulveda A, Sun W.
    Ann Oncol; 2013 Dec 23; 24(12):3061-5. PubMed ID: 24146220
    [Abstract] [Full Text] [Related]

  • 31. A Prognostic Index to Identify Patients With Intrahepatic Cholangiocarcinoma Who Could Benefit From Gemcitabine Plus Cisplatin.
    Lee SY, Kim HS, Choi YJ, Park KH, Shin SW, Kim YH, Tae Kim S.
    Am J Ther; 2016 Dec 23; 23(6):e1449-e1455. PubMed ID: 25285672
    [Abstract] [Full Text] [Related]

  • 32. Micro-RNA-130a-3p Regulates Gemcitabine Resistance via PPARG in Cholangiocarcinoma.
    Asukai K, Kawamoto K, Eguchi H, Konno M, Asai A, Iwagami Y, Yamada D, Asaoka T, Noda T, Wada H, Gotoh K, Nishida N, Satoh T, Doki Y, Mori M, Ishii H.
    Ann Surg Oncol; 2017 Aug 23; 24(8):2344-2352. PubMed ID: 28560603
    [Abstract] [Full Text] [Related]

  • 33. ARID1A Mutation from Targeted Next-Generation Sequencing Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer.
    Lee SH, Cheon J, Lee S, Kang B, Kim C, Shim HS, Park YN, Jung S, Choi SH, Choi HJ, Lee CK, Chon HJ.
    Cancer Res Treat; 2023 Oct 23; 55(4):1291-1302. PubMed ID: 37139666
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study.
    Golan T, Raitses-Gurevich M, Kelley RK, Bocobo AG, Borgida A, Shroff RT, Holter S, Gallinger S, Ahn DH, Aderka D, Apurva J, Bekaii-Saab T, Friedman E, Javle M.
    Oncologist; 2017 Jul 23; 22(7):804-810. PubMed ID: 28487467
    [Abstract] [Full Text] [Related]

  • 36. Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.
    Ruzzenente A, Fassan M, Conci S, Simbolo M, Lawlor RT, Pedrazzani C, Capelli P, D'Onofrio M, Iacono C, Scarpa A, Guglielmi A.
    Ann Surg Oncol; 2016 May 23; 23(5):1699-707. PubMed ID: 26717940
    [Abstract] [Full Text] [Related]

  • 37. Gemcitabine and cisplatin combination chemotherapy in intrahepatic cholangiocarcinoma as second-line treatment: report of four cases.
    Lee MA, Woo IS, Kang JH, Hong YS, Lee KS.
    Jpn J Clin Oncol; 2004 Sep 23; 34(9):547-50. PubMed ID: 15466829
    [Abstract] [Full Text] [Related]

  • 38. Postoperative adjuvant therapy following radical resection for intrahepatic cholangiocarcinoma: A multicenter retrospective study.
    Wang L, Deng M, Ke Q, Lou J, Zheng S, Bi X, Wang J, Guo W, Li F, Wang J, Zheng Y, Li J, Cheng S, Zhou W, Zeng Y.
    Cancer Med; 2020 Apr 23; 9(8):2674-2685. PubMed ID: 32072774
    [Abstract] [Full Text] [Related]

  • 39. Pemigatinib: A Review in Advanced Cholangiocarcinoma.
    Frampton JE.
    Target Oncol; 2024 Jan 23; 19(1):107-114. PubMed ID: 38206555
    [Abstract] [Full Text] [Related]

  • 40. Evolution of Treatment in Advanced Cholangiocarcinoma: Old and New towards Precision Oncology.
    Capuozzo M, Santorsola M, Landi L, Granata V, Perri F, Celotto V, Gualillo O, Nasti G, Ottaiano A.
    Int J Mol Sci; 2022 Dec 01; 23(23):. PubMed ID: 36499450
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.